FDA drug staffers opposed an HHS plan to let specialty pharmacies sell certain unproven injectable peptides, AP reports, and most scientific staff had limited input in drafting it. That is regulatory

What happened: FDA scientific staff opposed a Trump administration plan to loosen rules on unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., and had limited input in drafting it. Why it matters: FDA staffers warned the plan could undermine the agency's mission of keeping unproven health products off the U.S. market. HHS moved from an official regulation to a non-enforcement approach after FDA officials said scientific staff had major safety concerns.

FDA scientists opposed Trump administration's effort to ease peptides access.

FDA scientists opposed Trump administration's effort to ease peptides access. — impact context not separately stored; see What changed.